The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

A portable and wearable renal therapy system is provided. The system comprises: a purification device configured to remove toxins from process fluid and deliver a therapeutic substance to the process fluid; and a drug delivery device coupled to the purification device. The drug delivery device comprises: a reservoir for a fluid comprising a therapeutic substance; and a fluid connection coupling the drug delivery device with the purification device, the fluid connection configured for fluidly communicating the reservoir with the process fluid.

A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.

Devices, systems, and methods for depleting fluids of immunoglobulins and leukocytes are disclosed.

The invention provides apheresis devices and their use for substantial removal of all types of cfDNA for treatment of various diseases and during perfusion of an organ and/or anatomical cavity, to limit the negative effects of circulating cfDNA during organ transplantation and thus improve the quality and survival of transplanted organs, and reduce unfavorable transplantation outcomes such as transplant dysfunction, ischemia-reperfusion injury, graft rejection, and organ failure.

Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

An implantable device is for the selective removal of molecules from tissues or fluids so as to allow the selective removal of a particular molecule of interest (target molecule) from any type of fluid solution or tissue, including biological tissues or fluids. The device operates through the complementary action of specific-binding molecules (antibodies) directed against the target molecule inside the device. The device includes a nanoperforated membrane having pores larger than the target molecule but smaller than the antibodies, such that the fluid can be removed through a second catheter with a lower concentration of target molecules.

Apparatus and method for photo-chemical oxidation are disclosed herein. In one embodiment, a system for treating a dialysis fluid includes: a nanostructured photo-electrochemical anode; a source of light configured to illuminate the photo-electrochemical anode; and a cathode that is permeable to oxygen provided to the dialysis fluid and non-permeable to a liquid of the dialysis fluid. The photo-electrochemical anode is configured to remove urea from the dialysis fluid by converting the urea in the dialysis fluid into oxidation products through a photo electrochemical reaction.

Doxorubicin is extracted from blood using anionic material, such as a resin comprising sulfonated polystyrene divinylbenzene beads, and polyethersulfone membrane, or both. After exposing the resin and/or membrane to blood in order to remove doxorubicin therefrom, the doxorubicin maybe extracted from the resin and/or membrane by exposing the material to an extraction solution, sonicating the extraction solution to enhance release of the doxorubicin, and repeating the exposure and sonication in order to remove substantially all of doxorubicin from the resin.

A method for detoxifying a patient's blood by removing bilirubin from the patient's blood includes obtaining a batch of blood from the patient; controlling a pH of the blood so as to maintain the pH at approximately pH 7.4; controlling a temperature of the blood so as to maintain the temperature at approximately 37° C.; providing date pit-derived activated carbon; soaking the date pit-derived activated carbon within the blood for approximately 10-16 hours; and returning the detoxified blood to the patient.